Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression

Journal of Virology

Volumn 88, Issue 14, 2014, Pages 7929-7940

  Mukherjee, Anupam ^a   Shrivastava, Shubham ^a   Chowdhury, Joydip Bhanja ^a   Ray, Ranjit ^a   Ray, Ratna B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; GLYCOPROTEIN E1; MICRORNA; MICRORNA 181C; NONSTRUCTURAL PROTEIN 5A; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR HOXA10; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL GROWTH; CELL STRAIN; CELL STRAIN HUH7.5; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENOTYPE; GROWTH REGULATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOGENESIS; HUMAN; HUMAN CELL; LIVER CELL; MAMMAL; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN RNA BINDING; RNA TRANSCRIPTION; TISSUE DIFFERENTIATION; TISSUE GROWTH; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADULT; BIOPSY; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; GENE REGULATORY NETWORKS; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HOMEODOMAIN PROTEINS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER; MICRORNAS; TRANSCRIPTION FACTORS;

EID: 84904656568     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00787-14     Document Type: Article

References (37)

1. Gravitz L. 2011. Introduction: a smouldering public-health crisis. Nature 474:S2-S4. http://dx.doi.org/10.1038/474S2a.
2. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http: //dx.doi.org/10.1038/nm.3248.
3. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
4. Meister G, Tuschl T. 2004. Mechanisms of gene silencing by doublestranded RNA. Nature 431:343-349. http://dx.doi.org/10.1038/nature 02873.
5. Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215-233. http://dx.doi.org/10.1016/j.cell.2009.01.002.
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. 2009. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11:228-234. http://dx.doi.org/10.1038/ncb0309-228.
7. Roberts AP, Lewis AP, Jopling CL. 2011. The role of microRNAs in viral infection. Prog. Mol. Biol. Transl. Sci. 102:101-139. http://dx.doi.org/10.1016/B978-0-12-415795-8.00002-7.
8. Cullen BR. 2013. How do viruses avoid inhibition by endogenous cellular microRNAs? PLoS Pathog. 9:e1003694. http://dx.doi.org/10.1371/journal.ppat.1003694.
9. Conrad KD, Niepmann M. 2014. The role of microRNAs in hepatitis C virus RNA replication. Arch. Virol. 159:849-862. http://dx.doi.org/10.1007/s00705-013-1883-4.
10. Shrivastava S, Mukherjee A, Ray RB. 2013. Hepatitis C virus infection, microRNA and liver disease progression. World J. Hepatol. 5:479-486. http://dx.doi.org/10.4254/wjh.v5.i9.479.
11. Cullen BR. 2013. MicroRNAs as mediators of viral evasion of the immune system. Nat. Immunol. 14:205-210. http://dx.doi.org/10.1038/ni.2537.
12. Bhanja Chowdhury J, Shrivastava S, Steele R, Di Bisceglie AM, Ray R, Ray RB. 2012. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J. Virol. 86: 10221-10225. http://dx.doi.org/10.1128/JVI.00882-12.
13. Kanda T, Basu A, Steele R, Wakita T, Ryerse JS, Ray R, Ray RB. 2006. Generation of infectious hepatitis C virus in immortalized human hepatocytes. J. Virol. 80:4633-4639. http://dx.doi.org/10.1128/JVI.80.9.4633-4639.2006.
14. Shrivastava S, Bhanja Chowdhury J, Steele R, Ray R, Ray RB. 2012. Hepatitis C virus upregulates Beclin1 for induction of autophagy and activatesmTORsignaling. J. Virol. 86:8705-8712. http://dx.doi.org/10.1128 /JVI.00616-12.
15. Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, Barton DJ, Lemon SM. 2012. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc. Natl. Acad. Sci. U. S. A. 109:941-946. http://dx.doi.org /10.1073/pnas.1112263109.
16. Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. 2009. Regulation of the hepatitis C virus genome replication by miR-199a. J. Hepatol. 50:453-460. http://dx.doi.org/10.1016/j.jhep.2008.06.010.
17. Farré D, Roset R, Huerta M, Adsuara JE, Roselló L, Albà MM, Messeguer X. 2003. Identification of patterns in biological sequences at theALGGENserver:PROMOand MALGEN. Nucleic Acids Res. 31:3651-3653. http://dx.doi.org/10.1093/nar/gkg605.
18. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Ray R. 2012. Hepatitis C virus proteins inhibit C3 complement production. J. Virol. 86:2221-2228. http://dx.doi.org/10.1128/JVI.06577-11.
19. Banerjee A, Ray RB, Ray R. 2010. Oncogenic potential of hepatitis C virus proteins. Viruses 2:2108-2133. http://dx.doi.org/10.3390/v2092108.
20. Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE. 2008. Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology 149:2219-2229. http://dx.doi.org/10.1210/en.2007-1320.
21. Hsu PW, Lin LZ, Hsu SD, Hsu JB, Huang HD. 2007. ViTa: prediction of host microRNAs targets on viruses. Nucleic Acids Res. 35:D381-D385. http://dx.doi.org/10.1093/nar/gkl1009.
22. Sarnow P, Jopling CL, Norman KL, Schütz S, Wehner KA. 2006. MicroRNAs: expression, avoidance and subversion by vertebrate viruses. Nat. Rev. Microbiol. 4:651-659. http://dx.doi.org/10.1038/nrmicro1473.
23. Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. 2006. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 66:11590-11593. http://dx.doi.org/10.1158/0008-5472.CAN-06-3613.
24. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. 2009. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11:R27. http://dx.doi.org/10.1186/bcr2257.
25. Conti A, Aguennouz M, La Torre D, Tomasello C, Cardali S, Angileri FF, Maio F, Cama A, Germanò A, Vita G, Tomasello F. 2009. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J. Neurooncol. 93:325-332. http://dx.doi.org/10.1007/s11060-009-9797-4.
26. Ramji DP, Foka P. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365:561-575. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222736/pdf/12006103.pdf.
27. Hassan NM, Hamada J, Murai T, Seino A, Takahashi Y, Tada M, Zhang X, Kashiwazaki H, Yamazaki Y, Inoue N, Moriuchi T. 2006. Aberrant expression of HOX genes in oral dysplasia and squamous cell carcinoma tissues. Oncol. Res. 16:217-224.
28. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. 2005. The pathophysiology of HOX genes and their role in cancer. J. Pathol. 205:154-171. http://dx.doi.org/10.1002/path.1710.
29. Mohankumar KM, Xu XQ, Zhu T, Kannan N, Miller LD, Liu ET, Gluckman PD, Sukumar S, Emerald BS, Lobie PE. 2007. HOXA1-stimulated oncogenicity is mediated by selective upregulation of components of the p44/42MAPkinase pathway inhumanmammarycarcinoma cells. Oncogene 26:3998-4008. http://dx.doi.org/10.1038/sj.onc.1210180.
30. Wardwell-Ozgo J, Dogruluk T, Gifford A, Zhang Y, Heffernan TP, van Doorn R, Creighton CJ, Chin L, Scott KL. 2014. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome. Oncogene 33:1017-1026. http://dx.doi.org/10.1038/onc.2013.30.
31. Wang WB, Lew SE, Lee CK. 2011. STAT3 negatively regulates type I IFN-mediated antiviral response. J. Immunol. 187:2578-2585. http://dx.doi.org/10.4049/jimmunol.1004128.
32. Otsuka M, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook R, Das SC, Pattnaik AK, Beutler B, Han J. 2007. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. Immunity 27:123-134. http://dx.doi.org/10.1016/j.immuni.2007.05.014.
33. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. 2011. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res. 39:5157-5163. http://dx.doi.org/10.1093/nar/gkr067.
34. Chen Y, Shen A, Rider PJ, Yu Y, Wu K, Mu Y, Hao Q, Liu Y, Gong H, Zhu Y, Liu F, Wu J. 2011. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J. 25:4511-4521. http://dx.doi.org/10.1096/fj.11-187781.
35. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. 2010. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 88:169-175. http://dx.doi.org/10.1016/j.antiviral.2010.08.008.
36. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919-922. http://dx.doi.org/10.1038/nature 06205.
37. Zheng Z, Ke X, Wang M, He S, Li Q, Zheng C, Zhang Z, Liu Y, Wang H. 2013. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome. J. Virol. 87:5645-5656. http://dx.doi.org/10.1128/JVI.02655-12.